New Patent Granted for miRisten in China

AI SummaryClose X

Thalia Therapeutics plc has secured a new Chinese patent for its lead clinical-stage AML program, miRisten (THAT-001), extending intellectual property protection for this anti-microRNA-126 therapeutic. This patent covers the use of miRisten in the Chinese market, which is estimated to have approximately 30,400 new AML diagnoses in 2026. The company is currently evaluating miRisten in a Phase 1 trial for relapsed or refractory AML patients in the United States, with top-line data anticipated in the first half of 2027. This patent grant strengthens the company's IP portfolio, which already includes protection in the US, UK, Germany, France, Japan, and EPO countries.

Disclaimer*

UK 100

Latest directors dealings